RHÖN-KLINIKUM Aktiengesellschaft (ETR:RHK)
11.90
0.00 (0.00%)
Aug 21, 2025, 5:36 PM CET
ETR:RHK Revenue
RHÖN-KLINIKUM Aktiengesellschaft had revenue of 484.85M EUR in the quarter ending June 30, 2025, with 5.53% growth. This brings the company's revenue in the last twelve months to 1.92B, up 6.40% year-over-year. In the year 2024, RHÖN-KLINIKUM Aktiengesellschaft had annual revenue of 1.87B with 7.67% growth.
Revenue (ttm)
1.92B
Revenue Growth
+6.40%
P/S Ratio
0.42
Revenue / Employee
101.90K
Employees
14,067
Market Cap
796.57M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.87B | 133.13M | 7.67% |
Dec 31, 2023 | 1.73B | 73.57M | 4.43% |
Dec 31, 2022 | 1.66B | 69.95M | 4.40% |
Dec 31, 2021 | 1.59B | 45.15M | 2.92% |
Dec 31, 2020 | 1.55B | 65.12M | 4.40% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.38B |
Merck KGaA | 21.22B |
Bayer Aktiengesellschaft | 46.17B |
Fresenius SE & Co. KGaA | 22.28B |
Fresenius Medical Care AG | 19.52B |
Sartorius Aktiengesellschaft | 3.47B |
Fielmann Group AG | 2.33B |
Carl Zeiss Meditec AG | 2.18B |
RHÖN-KLINIKUM Aktiengesellschaft News
- 14 days ago - Rhoen-Klinikum Shines in H1 2025 with Strong Performance - Wallstreet:Online
- 3 months ago - Rhoen-Klinikum Steady in Q1 2025, Confirms Positive Outlook - Wallstreet:Online
- 5 months ago - Rhoen-Klinikum's Prof. Kaltenbach Exits After Stellar Year - Wallstreet:Online
- 5 months ago - EQS-News: RHÖN-KLINIKUM AG once again reports a successful financial year – CEO Prof. Kaltenbach leaves the Board of Management as planned - Wallstreet:Online
- 10 months ago - Rhoen-Klinikum Shines: Strong 9-Month Performance, Outlook Confirmed - Wallstreet:Online
- 1 year ago - RHÖN-KLINIKUM AG: Strong H1 2024 Performance, Confident Outlook Ahead - Wallstreet:Online
- 1 year ago - EQS-News: First half of 2024: RHÖN-KLINIKUM AG continues good business performance – outlook confirmed - Wallstreet:Online